WS
PACB icon

Wedbush Securities’s Pacific Biosciences PACB Stock Holding History

Wedbush Securities’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,759
Closed -$44K – 1263
2024
Q1 		$44K Sell
11,759
-3,058
-21% -$17.9K ﹤0.01% 1212
2023
Q4 		$145K Sell
14,817
-1,139
-7% -$9.31K 0.01% 1006
2023
Q3 		$133K Sell
15,956
-358
-2% -$4.09K 0.01% 972
2023
Q2 		$217K Sell
16,314
-72
-0.4% -$875 0.01% 897
2023
Q1 		$190K Buy
16,386
+5,339
+48% +$53.1K 0.01% 953
2022
Q4 		$90K Sell
11,047
-102
-0.9% -$879 ﹤0.01% 993
2022
Q3 		$65K Sell
11,149
-1,536
-12% -$8.81K ﹤0.01% 998
2022
Q2 		$56K Sell
12,685
-6,045
-32% -$36.7K ﹤0.01% 1028
2022
Q1 		$170K Sell
18,730
-2,215
-11% -$25.5K 0.01% 1011
2021
Q4 		$429K Buy
20,945
+505
+2% +$12.2K 0.02% 703
2021
Q3 		$522K Buy
20,440
+1,217
+6% +$36.1K 0.02% 590
2021
Q2 		$672K Buy
19,223
+7,648
+66% +$222K 0.03% 504
2021
Q1 		$386K Buy
+11,575
New +$405K 0.02% 678

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wedbush Securities's PACB Position: Q2 2024 in Review

Wedbush Securities sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 11,759 shares — an estimated $44K sold.

Wedbush Securities first reported a position in PACB in Q1 2021 and held it in 13 quarters. The position peaked at $672K in Q2 2021. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

  • Wedbush Securities reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
  • Wedbush Securities sold 11,759 Pacific Biosciences shares in Q2 2024, an estimated $44K.
  • Wedbush Securities first reported a position in Pacific Biosciences in Q1 2021 and held it in 13 quarters.
  • Wedbush Securities's Pacific Biosciences position peaked at $672K in Q2 2021.
  • 228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Wedbush Securities's 13F filing for Q2 2024, filed 7 Aug 2024.